Background and Aims: Biosimilar infliximab CT-P13 is approved for all indications of the originator product in Europe. Prospective data on its efficacy, safety, and immunogenicity in inflammatory bowel diseases are lacking. Methods: A prospective, nationwide, multicentre, observational cohort was designed to examine the efficacy, safety, and immunogenicity of CT-P13 infliximab biosimilar in the induction treatment of Crohn's disease [CD] and ulcerative colitis [UC]. Demographic data were collected and a harmonised monitoring strategy was applied. Early clinical remission, response, and early biochemical response were evaluated at Week 14, steroid-free clinical remission was evaluated at Week 30. Therapeutic drug level was monitored using a conventional enzyme-linked immunosorbent assay. Results: In all, 210 consecutive inflammatory bowel disease [126 CD and 84 UC] patients were included in the present cohort. At Week 14, 81.4% of CD and 77.6% of UC patients showed clinical response and 53.6% of CD and 58.6% of UC patients were in clinical remission. Clinical remission rates at Week 14 were significantly higher in CD and UC patients who were infliximab naïve, compared with those with previous exposure to the originator compound [p < 0.05]. Until Week 30, adverse events were experienced in 17.1% of all patients. Infusion reactions and infectious adverse events occurred in 6.6% and 5.7% of all patients, respectively. Conclusions: This prospective multicentre cohort shows that CT-P13 is safe and effective in the induction of clinical remission and response in both CD and UC. Patients with previous infliximab exposure exhibited decreased response rates and were more likely to develop allergic reactions.
Introduction
Biosimilars are biological medicines that enter the market after the patent expiration of the original reference product. The first biosimilar monoclonal antibody, biosimilar infliximab CT-P13 [Remsima®, Celltrion, Republic of Korea and Inflectra®, Hospira, UK] received marketing authorisation from the European Medicine Agency [EMA] in June 2013 for all indications of the originator product. 1 This includes the use of biosimilar infliximab in inflammatory bowel diseases [IBD] , as an extrapolated indication based on comparative clinical studies in ankylosing spondylitis [PLANETAS] and rheumatoid arthritis [PLANETRA] . 2, 3 According to a European survey among gastroenterologists in 2013, there was a lack of confidence in using biosimilar infliximab in IBD. 4 Concerns have also been raised by several national societies with regard to extrapolated indications. 5, 6 These concerns included the dosing of infliximab, which differs between indications, 5 mg/kg in IBD and 3 mg/kg in rheumatoid arthritis. The use of concomitant immunosuppressive medication is more common in rheumatological indications compared with IBD. Accordingly, in the PLANETRA study, all patients received combination treatment with methotrexate in addition to the originator or biosimilar infliximab. 2 Additionally, there is difference in the downstream effects of anti-tumour necrosis factor-α [anti-TNF] medications in rheumatological conditions and in IBD. 7, 8 In support of extrapolated indications, the European Medicines Agency [EMA] requires stringent analytical and pre-clinical comparability exercises as well as comparative clinical studies to demonstrate biosimilarity. 9 Biosimilars may lead to significant cost savings and easier access to biologicals with sustained level of care.
As of May 2014, the Hungarian National Health Fund only reimburses the biosimilar infliximab [Inflectra ® , Hospira, UK] for new induction treatment of IBD patients. New induction was defined as no infliximab treatment with the originator [or the biosimilar] compound in the previous 12 months. Switching from the originator compound to the biosimilar infliximab is not allowed according to current regulations.
Data on the use of the biosimilar infliximab CT-P13 in IBD are limited. 10, 11 Therefore, we designed a prospective, nationwide, multicentre, observational study to examine the efficacy, safety, and immunogenicity of CT-P13 infliximab biosimilar in induction and maintenance of remission in Crohn's disease [CD] and ulcerative colitis [UC].
Material and Methods

Patients
The induction phase of this multicentre, nationwide prospective observational study was conducted between May 2014 and May 2015 at 12 sites in Hungary; the maintenance phase is still ongoing. Consecutive IBD patients starting on infliximab biosimilar were prospectively enrolled in the study. Eligible patients were older than 18 years and were previously diagnosed either with CD or with UC based on clinical, biochemical, endoscopic, and histological findings. In the BCG [Bacillus Calmette-Guerin]-vaccinated population, patients with positive tuberculin skin tests and positive quantiferon assay [QuantiFERON ® -TB Gold, Cellestis Limited, Carnegie, VIC, Australia] were ineligible. Standard chest radiographs were also obtained during screening. Eligible Crohn's patients had moderate to severe therapy-refractory or steroid-dependent luminal disease, or therapy-refractory simple fistulising disease or complex fistulas. Eligible patients with ulcerative colitis had therapy-refractory, steroid-dependent or severe acute steroid-refractory colitis. None of the patients received infliximab treatment with the originator compound within 12 months before initiation of the biosimilar infliximab. 
Study design
Statistical analysis
Data were analysed with the use of SPSS 20.0 software. Descriptive statistics were used to characterise patients' demographics, early clinical remission and response rates, and adverse events. Clinical response, remission rates, and antidrug antibody positivity rates were compared between infliximab-exposed and naïve patients by chi 2 test or Fisher exact test. Biochemical response and infliximab trough levels were evaluated by t-test with separate variance estimates or oneway analysis of variance [ANOVA], using Scheffe post-hoc analysis, as appropriate; p < 0.05 was considered statistically significant. , AbbVie]. At baseline, 47.6% and 62.5% of CD patients received concomitant steroid and thiopurine therapy, respectively. The median disease duration in UC patients was 4 years; 57.1% of UC patients had extensive disease. At inclusion, 64.7% and 57.3% of patients were on concomitant steroid and thiopurine therapy, respectively. Detailed patient demographic data are presented in Table 1 . Clinical response rates at Week 6 were significantly higher in both CD and UC infliximab-naïve patients compared with those previously exposed to the originator compound [87.3 vs. 51.7% in CD and 81.4 vs. 60% in UC, p < 0.05 and p < 0.05, respectively Figure 2c ]. Clinical remission rates at Week 14 were significantly higher both in CD and UC patients without previous exposure to the originator infliximab compared with those previously exposed [60.9% vs. 35,7% in CD and 65.1% vs. 33.3% in UC, p < 0.05 and p < 0.05, respectively, Figure 2d] 
Results
Patients and follow-up
Early clinical remission and response
Biochemical response
In CD patients the mean CRP level was 20.9 mg/l at baseline, which decreased to 10.6 mg/l at Week 14 [p = 0.02, Figure 4a 
Adverse events
Up to Week 30, adverse events had occurred in 17.1% of all patients. Infusion reactions occurred in 6.7% [n = 14] of CT-P13 treated patients. Ten of the 14 patients experiencing infusion reaction of any severity had previously received the originator infliximab. Infusion reactions occurred in a significantly higher proportion of patients with previous infliximab exposure compared with naïve patients [27% vs. 2.5%, p < 0.001]. No infusion reactions occurred in patients with previous exposure to adalimumab. Possible delayed hypersensitivity occurred in one patient. Infectious adverse events occurred in 5.7% of all patients; one patient had invasive fungal sepsis, which resulted in her death [ Table 2 ].
Discussion
Our results show that biosimilar infliximab CT-P13 induces and maintains high clinical remission and response rates in both CD and UC patients up to week 30. There was a significant difference in the early response and remission rates between patients previously exposed to the originator compound as compared with the infliximab-naïve patients. This was associated with significantly higher baseline ADA positivity in both CD and UC patients previously IQR, interquartile range; CD, Crohn's disease; UC, ulcerative colitis; IFX, infliximab; 5ASA, 5-aminosalicylates; AZA, azathioprine; CsA, cyclosporine A; TNF, tumour necrosis factor; ADA, anti-drug antibody; PDAI, Pouchitis Disease Activity Index; CDAI, Crohn's Disease Activity Index.
exposed to the originator compound. Clinical improvement during induction was coupled with decreased biochemical activity in both CD and UC as compared with baseline.
The ACCENT I trial demonstrated that 39% of Week 2-responder CD patients exhibited clinical remission at Week 30 when treated with infliximab 5 mg/kg compared with 21% in placebo-treated responders. 16 Additionally, real-life clinical data with the originator support high response and remission rates during induction in CD patients. [17] [18] [19] In comparison, clinical response and remission in CD patients after the induction treatment with CT-P13 were 82% and 54%, respectively, and 67.2% of Week 14-responder CT-P13-treated CD patients maintained clinical response up to week 30. This is in line with an earlier retrospective national initiative, which demonstrated 86% response and 46% remission rates in CD from the same background population after induction treatment with the originator compound. 20 In the ACT 1 and ACT 2 trials, 69% and 64% of UC patients who received 5 mg/kg of infliximab had a clinical response at Week 8 and 49% and 41% of patients maintained response at Week 30, respectively.
14 In comparison, in our real-life cohort with CT-P13, clinical response was 78% at Week 14. Additionally, 80% of Week-14 UC responders sustained clinical response at Week 30. This is comparable to a retrospective, multicentre analysis that showed 22% primary non-response to the originator compound in UC. 21 Our findings are also in line with the results of a retrospective study and a case series regarding the efficacy of CT-P13 in IBD. 10, 11 In the present cohort, drug-related adverse events were experienced in 17.1% of patients until Week 30. This is remarkably lower than adverse events reported in either the PLANETAS or the PLANETRA study.
2, 3 We did not detect any cases of latent tuberculosis during the study period in our BCG-vaccinated population. Additionally, changes in the clinical laboratory parameters per se were not considered a safety endpoint. The rate of infusion-related reactions with CT-P13 in IBD was comparable to those reported in the rheumatological studies [6.7% vs. 6.6 and 3.9%]. Of note, IBD patients in the present cohort were not routinely premedicated with antihistamine, were not necessarily on concomitant immunosuppressives, and may have been previously exposed to the originator compound. In our study population. 22% of CD and 11% of UC patients had previously received the originator infliximab. Re-initiation of infliximab treatment has previously been shown to be an effective and safe therapeutic option. 22, 23 According to the results of the present study, a word of caution is needed, since the majority of early infusion reactions occurred in patients with a previous anti-TNF exposure by the originator molecule and a drug holiday beyond 1 year. Therefore a risk-benefit evaluation is recommended before initiating a long drug holiday in patients in remission, and further data are warranted.
Pharmacokinetic evaluation of CT-P13 in IBD has not been previously reported. In our present study, mean TLs were 24.8, 18.4, and 4.8 μg/ml in CD and 19.3, 36.2, and 3.3 μg/ml in UC at Weeks 2, 6, and 14, respectively. In comparison, a post-hoc analysis of the ACCENT I trial found that median Week 14 trough levels of patients with and without sustained response to infliximab induction with 5 mg/kg, were 4.0 and 1.9 μg/ml, respectively 24 Interestingly, in our cohort patients with previous infliximab exposure had a tendency towards lower early TLs compared with naïve patients. This was associated with significantly higher baseline ADA positivity [4% vs. 24%] and lower early response and remission rates in patients previously exposed to the originator compound. ADA positivity in the CT-P13-treated infliximabnaïve and previously exposed CD patients were 24.2% and 38.5% at Week 14, respectively. In comparison, ADA positivity was previously reported to range between 12.5% to 43% and 0.9% to 14% in infliximab-naïve patients with scheduled infliximab infusions of the originator compound, depending on the administration of concomitant immunosuppression. 25 In comparison, in a head-to-head Japanese trial in rheumatoid arthritis, CT-P13 or infliximab was administered in combination with methotrexate and ADA were detected in 19.6% of patients in the CT-P13 group and 15.1% of patients in the infliximab group at Week 14. 26 The development of antibodies has previously been associated with increased risk of infusion reactions and reduced response to treatment. 27 Additionally, when re-initiating the infliximab therapy after a drug holiday, when antibodies to infliximab were detectable, the hazard ratio for infusion reaction was 7.7. 23 This underlines our findings that 10 of 14 patients who experienced infusion reaction of any severity had previously received the originator infliximab. Furthermore, it has recently been demonstrated that anti-infliximab antibodies in IBD patients recognise and cross-react with CT-P13 and neutralise each drug's activity. 28 In contrast, anti-adalimumab antibodies do not cross-react with CT-P13. 28 Consistently, no infusion reactions occurred in patients with previous adalimumab exposure in our cohort. Consequently, ADA to infliximab that were detected at baseline in our previously exposed patient population could have been responsible for the reduced rate of early clinical response. The clinical importance of ADAs detected at baseline [five patients, transient in three patients] in the infliximab-naïve population needs further investigation.
This study is a nationwide, multicentre, prospective cohort with a harmonised monitoring strategy. However, there are limitations to acknowledge. During the induction phase, only clinical and biochemical endpoints were evaluated and therefore the study lacks an early endoscopic endpoint. Nevertheless, following the national monitoring strategy, endoscopic evaluation will be available at Week 54 both in CD and in UC patients. Our study did not aim to evaluate interchangeability, as switching from the originator compound to the biosimilar [or vice versa] was not allowed by the national health authorities. However, preliminary retrospective data are showing favourable outcome, and a randomised, double-blind, parallelgroup study, the NOR-SWITCH study [ClinicalTrials.gov identifier: NCT02148640] is currently being pursued. 10, 11, 29 Despite the EMA's strict regulations to granting marketing authorisation to the first biosimilar monoclonal antibody, several concerns have been raised regarding its administration in IBD. So far only limited data from retrospective real-life experience have been available on the use of the biosimilar infliximab CT-P13 in IBD. 10, 11 Therefore, this nationwide cohort was designed to satisfy this unmet need and prospectively evaluate the efficacy and safety of CT-P13 in IBD.
To conclude, this prospective multicentre cohort shows that CT-P13 is effective and safe in the induction of clinical remission and response in both CD and UC. Efficacy and safety of CT-P13 reported herein is comparable to those of observational studies of the originator compound. Importantly, induction treatment with the biosimilar infliximab was less effective in patients previously exposed to the originator compound. Further data are warranted to evaluate the efficacy of CT-P13 in maintaining remission in IBD.
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